Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.41 (market cap $77.43B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 36.2× Recursion Pharmaceuticals Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| MDLZ | RXRX | |
|---|---|---|
Market Cap | $77.43B | $2.14B |
Volume | 7,695,104 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $6.79 |
52-Week Low | $51.51 | $2.84 |
Typical Hold Time | 107 Days | 23 Days |
Enterprise Value | $97.78B | $1.66B |
Dividend Yield | 3.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $60.67, up 2.17% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $0.73 exceeding expectations. Recent dividend increase to $0.52 per share and positive cash flow trends support the investment case. Valuation metrics include P/E of 22.22 and P/S of 1.97, while revenue growth continues with 2025 revenue reaching $38.54 billion.
MDLZ presents a compelling opportunity with 76% analyst buy ratings and $70.29 consensus price target representing 16% upside. The company demonstrates pricing power and emerging market momentum, though cocoa cost pressures and margin compression from 13.76% in 2023 to 6.36% in 2025 remain key watchpoints. Strong brand portfolio and defensive characteristics provide stability amid market volatility.
RXRX trades at $3.95, down 7.49% in the last session, reflecting ongoing volatility. The company reported a net loss of $644.76M in 2025, with a negative net income margin of -961.97%, though recent quarters have shown mixed earnings beats. Technical indicators are bullish overall, with moving averages signaling strength. Strategic partnerships, such as the extended data license with Tempus AI (Business Wire, 2026-09-21), aim to bolster its AI-driven drug discovery platform, but high cash burn remains a concern.
The outlook is cautious; while analyst consensus is 40% buy and 60% hold (MarketBeat, 2026-09-20), the stock faces significant risks from persistent losses and slow revenue growth. Upside potential hinges on pipeline success, but investors must weigh the high valuation (P/S of 37.14) against operational challenges and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
